Denton John Russel sold 7,500 shares of Caris Life Sciences, Inc. at $31.82 for −$239k on Sep 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Sep 23, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$238,626Shares × reported price
Shares traded
7,500Common Stock
Price per share
$31.82Reported price. Read footnotes for ranges.
% of reported position traded
4.11%This security and ownership context
Holdings after
174,855Direct
Trade date
Sep 22, 2026Sell
Filed
Sep 23, 2026, 5:06 PM ET1-day reporting delay
Accession
0002071923-26-000007Code S · Transaction 228488
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 182,355 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CAI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CAI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −17%1w ago −10%1d ago −3.2%
Returns since7d −3.2%30d +1.1%90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4.